Trials / Completed

CompletedNCT00134186

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 43 (planned)

Sponsor: Pharmacyclics LLC. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

Conditions

Carcinoma, Renal Cell
Urogenital Neoplasms
Urologic Neoplasms
Kidney Neoplasms

Interventions

Type	Name	Description
DRUG	motexafin gadolinium

Timeline

First posted: 2005-08-24
Last updated: 2007-03-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00134186. Inclusion in this directory is not an endorsement.